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ABSTRACT The occurrence of resistance to last-resort antibiotics was evaluated
among Enterobacteriaceae isolates recovered from hospitalized children in a remote Afri-
can archipelago, São Tomé and Príncipe, where there is limited access to those antibiot-
ics. Fifty patients were screened for colonization by carbapenem-, pan-aminoglycoside-,
or polymyxin-resistant Enterobacteriaceae. A total of 36 isolates (including 30 Esche-
richia coli and 4 Klebsiella pneumoniae) were recovered from 23 patients, including
26 isolates harboring the blaOXA-181 carbapenemase gene, a single isolate harboring
the 16S rRNA methylase gene rmtB encoding pan-resistance to aminoglycosides, and
8 isolates coharboring both genes. A single isolate possessed the plasmid-borne colis-
tin resistance gene mcr-1. A high clonal relationship was found for OXA-181-producing
E. coli (4 clones), and conversely, three of the four OXA-181-producing K. pneu-
moniae isolates were clonally unrelated. This study overall showed a high prevalence
of resistance to last-resort antibiotics in this country, where no epidemiological data
were previously available.
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The increasing occurrence of resistance to last-resort drugs in Gram-negative bac-teria is one of the major public health concerns, particularly in regard to Entero-
bacteriaceae. Carbapenems are among those last-resort antibiotics, because of their
wide range of activity (1), but their effectiveness may be compromised by the produc-
tion of carbapenemases (2). Acquired carbapenemases in Enterobacteriaceae belong to
three different Ambler classes (3): class A, including the serine carbapenemases KPC,
NMC/IMI, and SME; class B, including the metallo--lactamases VIM, IMP, and NDM; and
class D, including OXA-48-like -lactamases (with OXA-48 and OXA-181 variants being
predominant) (4).
OXA-48, originally identiﬁed in a Klebsiella pneumoniae clinical isolate in Turkey, is
now known to be widespread among enterobacterial species in Europe and in several
African countries (5, 6). Many nosocomial outbreaks due to OXA-48-producing K.
pneumoniae have been reported, but OXA-48 producers may also be detected in the
community, especially in Escherichia coli (4). OXA-181 is a close derivative of OXA-48 (7)
that has been identiﬁed in the Indian subcontinent, in China, and in some African
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countries. It differs from OXA-48 by four amino acids while sharing a very similar
hydrolytic proﬁle (8).
The epidemiology of carbapenemases in Africa remains quite unknown, since some
of the local reports correspond to scattered cases only, and some other external reports
are based on observations made in other continents after patient transfers. Nonethe-
less, OXA-48-like and NDM-like enzymes seem to be the main carbapenemases iden-
tiﬁed in this continent (4), with the exception of South Africa, where NDM and KPC
producers have additionally been found (9, 10). Isolates producing OXA-48-like en-
zymes seem to be predominant in the Northern part of the continent (4, 10), and strains
producing OXA-181 are widespread in South Africa, Nigeria, and Angola (11–13). All of
those areas are in mainland Africa and have connections to many other countries,
which may explain the recurrent importations and spread of those resistance determi-
nants.
Our aim was to investigate a remote African area, with limited population exchanges
and limited access to antibiotic usage. Hence, we investigated the occurrence and
genetic characteristics of either carbapenem-, pan-aminoglycoside-, or polymyxin-
resistant Enterobacteriaceae recovered from rectal samples of pediatric patients in a
hospital of São Tomé and Príncipe.
RESULTS
From the 50 patients, a total of 36 isolates were recovered on the different selective
media used. Those 36 isolates were recovered from 23 different patients, who were all
hospitalized for more than 48 h. When several isolates presented the exact same
phenotype, only one was retained for further analysis. A total of 34 carbapenem-
resistant enterobacterial isolates were recovered, of which 30 were Escherichia coli and
4 were K. pneumoniae. The rate of colonization by carbapenem-resistant Enterobacte-
riaceae among patients was therefore 44% (22/50). They were all found to produce the
same carbapenemase, OXA-181. Nine isolates (recovered from eight patients; coloni-
zation rate, 16%) were found to be pan-resistant to aminoglycosides, and all possessed
the rmtB 16S rRNA methylase gene. Noticeably, 8 of the 9 rmtB-positive strains
coharbored the blaOXA-181 gene.
A single colistin-resistant E. coli isolate was also recovered, being positive for the
mcr-1 gene. That isolate did not exhibit any other resistance, being fully susceptible to
-lactams.
A majority of the blaOXA-181-positive isolates copossessed the extended-spectrum
-lactamase (ESBL)-encoding gene blaCTX-M-15. All the 30 blaOXA-181-positive E. coli
isolates coharbored blaTEM-1, and 60% (18/30) coharbored blaCTX-M-15. Moreover, 8 of
those 18 blaCTX-M-15- and blaOXA-181-positive isolates also harbored the RMTase gene
rmtB. Four of the ﬁve K. pneumoniae isolates harbored the blaOXA-181 gene, with three
of them copossessing blaTEM-1, and a single isolate coharboring blaCTX-M-15. The only K.
pneumoniae strain that did not possess blaOXA-181 coharbored the blaTEM-1, blaCTX-M-15,
and rmtB genes (Table 1).
Pulsed-ﬁeld gel electrophoresis (PFGE) analysis showed a quite high clonality rate
among the E. coli isolates (data not shown), with four clones (EC-1 to EC-4) identiﬁed
from the 31 strains. E. coli clones EC-1 (n  12), EC-2 (n  10), and EC-3 (n  8) all
produced the carbapenemase OXA-181. E. coli EC-3 additionally possessed the 16S
rRNA methylase gene rmtB. Only a single strain was associated with EC-4, correspond-
ing to the mcr-1-positive E. coli isolate. By using multilocus sequence typing ([MLST]
considering alleles adk-fumC-gyrB-icd-mdh-purA-recA), we found that those four clones
actually corresponded to four novel sequent types (STs), being, however, quite closely
related (single locus variants [SLV]) to some previously reported. Indeed, EC-1 (MLST:
550/11/4/8/8/13/2) is an SLV of ST1163, EC-2 (8/977/5/220/8/8/2) an SLV of ST410, EC-3
(20/45/56/106/7/534/46) an SLV of ST167, and EC-4 (635/4/12/1/20/18/7) an SLV of
ST1408.
In contrast to that for E. coli, a high clonal diversity was identiﬁed among the K.
pneumoniae isolates, with 4 different PFGE proﬁles identiﬁed among the ﬁve isolates
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TABLE 1 Genetic features associated with the isolates in this collection
Strainsa Species
Resistance
determinants
Plasmid
size (kb)
Incompatibility
groupb
PFGE
proﬁle
MIC (g/ml)c
IPM MEM CAZ AMK GEN CST
Carbapenem resistant
STP1 E. coli OXA-181, TEM-1 66 IncX3 EC-1 16 4 32
STP2 E. coli OXA-181, TEM-1 66 IncX3 EC-1 16 4 32
STP3 E. coli OXA-181, TEM-1 66 IncX3 EC-1 16 4 32
STP4A E. coli OXA-181, TEM-1 66 IncX3 EC-1 16 4 32
STP5 E. coli OXA-181, TEM-1 66 IncX3 EC-1 16 4 32
STP6 E. coli OXA-181, TEM-1 66 IncX3 EC-1 16 4 32
STP7 E. coli OXA-181, TEM-1 66 IncX3 EC-1 16 4 32
STP8 E. coli OXA-181, TEM-1 66 IncX3 EC-1 16 4 32
STP9A E. coli OXA-181, TEM-1 66 IncX3 EC-1 16 4 32
STP10A E. coli OXA-181, TEM-1 66 IncX3 EC-1 16 4 32
STP11A E. coli OXA-181, TEM-1 66 IncX3 EC-1 16 4 32
STP12A E. coli OXA-181, TEM-1 66 IncX3 EC-1 16 4 32
STP13A E. coli OXA-181, CTX-M-15,
TEM-1
60 IncX3 EC-2 32 8 256
STP14A E. coli OXA-181, CTX-M-15,
TEM-1
60 IncX3 EC-2 32 8 256
STP15A E. coli OXA-181, CTX-M-15,
TEM-1
60 IncX3 EC-2 32 8 256
STP4B E. coli OXA-181, CTX-M-15,
TEM-1
60 IncX3 EC-2 32 8 256
STP16A E. coli OXA-181, CTX-M-15,
TEM-1
60 IncX3 EC-2 32 8 256
STP9B E. coli OXA-181, CTX-M-15,
TEM-1
60 IncX3 EC-2 32 8 256
STP17 E. coli OXA-181, CTX-M-15,
TEM-1
60 IncX3 EC-2 32 8 256
STP18 E. coli OXA-181, CTX-M-15,
TEM-1
60 IncX3 EC-2 32 8 256
STP19 E. coli OXA-181, CTX-M-15,
TEM-1
60 IncX3 EC-2 32 8 256
STP20 E. coli OXA-181, CTX-M-15,
TEM-1
60 IncX3 EC-2 32 8 256
STP11B E. coli OXA-181, CTX-M-15,
TEM-1, RmtB
NDd IncX3 EC-3 16 2 256
STP14B E. coli OXA-181, CTX-M-15,
TEM-1, RmtB
ND IncX3 EC-3 16 2 256
STP21 E. coli OXA-181, CTX-M-15,
TEM-1, RmtB
ND IncX3 EC-3 16 2 256
STP22A E. coli OXA-181, CTX-M-15,
TEM-1, RmtB
ND IncX3 EC-3 16 2 256
STP15B E. coli OXA-181, CTX-M-15,
TEM-1, RmtB
ND IncX3 EC-3 16 2 256
STP16B E. coli OXA-181, CTX-M-15,
TEM-1, RmtB
ND IncX3 EC-3 16 2 256
STP10B E. coli OXA-181, CTX-M-15,
TEM-1, RmtB
ND IncX3 EC-3 16 2 256
STP11C E. coli OXA-181, CTX-M-15,
TEM-1, RmtB
ND IncX3 EC-3 16 2 256
STP11D K. pneumoniae OXA-181, CTX-M-15 66 IncX3 KP-1 32 8 256
STP12B K. pneumoniae OXA-181, TEM-1 66 IncX3 KP-2 64 8 0.25
STP13B K. pneumoniae OXA-181, TEM-1 66 IncX3 KP-3 16 4 256
STP9C K. pneumoniae OXA-181, TEM-1 66 IncX3 KP-3 16 4 256
Pan-aminoglycoside resistant
STP23 K. pneumoniae TEM-1, CTX-M-15,
RmtB
ND ND KP-4 256 256 256
Colistin resistant
STP22B E. coli MCR-1 54 IncX4 EC-4 32
aDifferent numbers indicate different patients and associated letters, if any, indicate different isolates recovered from the same patient.
bIncompatibility group of the plasmid harboring the carbapenemase gene.
cIPM, imipenem; MEM, meropenem; CAZ, ceftazidime; AMK, amikacin; GEN, gentamicin; CST, colistin.
dND, not determined.
3
htt
p:/
/do
c.r
ero
.ch
(KP-1 to KP-4). MLST identiﬁed those four clones corresponding to four distinct STs,
namely, ST18, ST3346, ST1035, and ST3347.
Mating-out assays followed by plasmid analysis revealed a single ca. 64-kb
blaOXA-181-bearing plasmid possessing an IncX3 backbone in all the blaOXA-181-positive
isolates (data not shown). Themcr-1 gene was identiﬁed on a 54-kb plasmid, possessing
an IncX4 backbone (data not shown). Mating-out assays and electro-transformation
assays performed with E. coli isolates coproducing OXA-181 and RmtB remained
unsuccessful.
PCR mapping of the blaOXA-181-positive isolates was performed to verify whether the
close vicinity of the carbapenemase gene was actually similar to that previously
identiﬁed on plasmid pOXA-181 recovered in Angola (13). As observed with pOXA-181,
the insertion sequence ISKpn19 was identiﬁed upstream of the blaOXA-181 gene in all
strains. Conversely, the IS3000 element identiﬁed downstream of the blaOXA-181 gene in
pOXA-181 was not found in our collection.
DISCUSSION
The dissemination of last-resort-antibiotic-resistant bacteria is becoming one of the
most important health issues worldwide. In this study, we evaluated the prevalence of
clinically relevant antibiotic resistance traits among Enterobacteriaceae recovered from
patients in the main hospital of São Tomé and Príncipe. We identiﬁed a high rate of
colonization by carbapenemase-producing enterobacterial isolates (44% of the pa-
tients), with OXA-181 being the only carbapenemase identiﬁed. This observation is of
note, considering that no patient received carbapenem-based antibiotherapy in that
hospital, where such antibiotics are not available.
The presence of the blaOXA-181 gene is remarkable, since it has been previously
identiﬁed in other African countries, including Angola, Nigeria, South Africa, and across
several Northern African countries. We recently conducted similar studies in one
pediatric hospital in Angola, another Portuguese-speaking African country (13, 14). In
those studies, a large number of carbapenemase-producing isolates also possessed the
blaOXA-181 gene, although blaNDM-like genes were also commonly identiﬁed. Of note,
the four blaOXA-181-positive K. pneumoniae isolates recovered corresponded to three
distinct clones, therefore ruling out a nosocomial transmission in most cases. Those
strains did not correspond to known STs identiﬁed elsewhere.
In contrast, a clonal relationship was found among the numerous blaOXA-181-
positive-producing E. coli recovered. Considering that most patients had been hospi-
talized for quite a long period of time, and owing to the very poor conditions of
hospitalization of those patients (very limited nursing staff, poor hygiene within the
wards, etc.), it is likely that nosocomial transmission was quite frequent in that hospital,
explaining such clonal dissemination and such a high rate of multidrug-resistant
isolates.
One of the E. coli clones (EC-2) possessing blaCTX-M-15 was found genetically close to
an ST410 background. This is noteworthy, since a series of blaCTX-M-15- and blaOXA-181-
positive ST410 E. coli isolates have been identiﬁed in Italy (15) and Denmark (16). This
clone is also predominant among OXA-181 producers in Canada (17). Furthermore, by
investigating ESBL-producing E. coli isolates of diverse sources in Germany (wildlife,
environment, animal, and humans), Schauﬂer et al. (18) identiﬁed this same ST410 clone
in all those sources, highlighting its very wide dissemination.
Of note, a similar self-conjugative blaOXA-181-bearing IncX3-type plasmid was iden-
tiﬁed in São Tomé and Príncipe and in Angola. This plasmid was identiﬁed in variable
species and strain backgrounds, highlighting its wide spread. Even though this plasmid
did not carry any other resistance determinant, and even though OXA-181 does not
confer resistance to those molecules, most of the isolates were resistant to broad-
spectrum cephalosporins. The reason was that those isolates coharbored an ESBL-
encoding gene, namely, the worldwide spread blaCTX-M-15 gene, which is also com-
monly identiﬁed coassociated with blaOXA-48-bearing plasmids (4).
Interestingly, the genetic environment of the blaOXA-181 gene shared some elements
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with those identiﬁed in China (19) and in Angola (13, 14). That gene was identiﬁed on
an IncX3-type plasmid, and upstream it was ﬂanked by ISEcp1 truncated by IS3000.
Remarkably, IncX3-type plasmids harboring the blaOXA-181 gene seem to be widespread
in Asia. A recent study showed that blaOXA-181-positive isolates in Switzerland from
fresh vegetables originating from Asia indeed harbored similar genetic features (20).
Furthermore, eight isolates in our collection were positive for the 16S rRNA methylase
gene rmtB, which is also widespread in China, and particularly, among animal isolates
(21, 22).
Our data support the importance of surveillance of multidrug-resistant Gram-
negative bacteria. This study was done in a remote environment, in a hospital where
broad-spectrum and last-resort antibiotics are not available (particularly carbapenems)
but where carbapenemase genes are widespread. It further highlights that Africa may
act as an important reservoir for OXA-181 producers, as likewise, Asia. Owing to the fact
that OXA-181 (like OXA-48) has a peculiar hydrolytic spectrum, including penicillins and
carbapenems but sparing broad-spectrum cephalosporins, and is resistant to usual
-lactamase inhibitors (clavulanic acid and tazobactam), we might speculate that
the driving factors of selection of this carbapenemase could simply be correspond-
ing to penicillins or penicillin--lactamase inhibitor combinations in that geograph-
ical area.
MATERIALS AND METHODS
Bacterial isolates and susceptibility testing. A total of 50 rectal swabs were collected from
hospitalized children (n  50) during 3 days in March 2018 at the Ayres de Menezes Hospital of Sao
Tome, Sao Tome and Principe. Samples were collected from different wards, from children suffering from
diverse diseases, including respiratory failures, burns, HIV-related immunodeﬁciency, malaria, and
trauma. Whether patients previously received an antibiotic regimen was quite unclear; nonetheless, it is
worth highlighting that among the few antibiotics available, there were amoxicillin, cefuroxime, cipro-
ﬂoxacin, erythromycin, trimethoprim-sulfamethoxazole, and gentamicin. The samples were incubated in
Luria-Bertani (LB) broth (5 ml) overnight. From each sample, one calibrated loop (10 l) was plated on
each of the three selective media, i.e., (i) CHROMagar mSuperCARBA (CHROMagar, Paris, France) (23), (ii)
SuperAminoglycoside (Drigalski agar supplemented with 30 g/ml gentamicin, 30 g/ml amikacin, 10
g/ml vancomycin, and 5 g/ml amphotericin B) (24), and (iii) SuperPolymyxin (eosin methylene blue
agar supplemented with 1 g/ml colistin, 10 g/ml daptomycin, and 5 g/ml amphotericin B) (25). The
isolates that were selected were identiﬁed at the species level using the API20E system (bioMérieux, La
Balme-les-Grottes, France). Antimicrobial susceptibility testing was performed using the disc diffusion
method, and interpreted according to the CLSI recommendations (26), except for colistin, for which
susceptibility was only evaluated by broth microdilution (BMD). Carbapenemase activity was assessed by
using the Rapidec Carba NP test (27) for each of the isolates growing on the mSuperCARBA plates. MICs
were determined by BMD as recommended by EUCAST (www.eucast.org).
Molecular analysis. The identiﬁcation of carbapenemase and extended-spectrum -lactamase
(ESBL) genes was performed by PCR using previously reported primers (28–31). Additionally, the
aminoglycoside resistance 16S rRNA methylase genes (armA, rmtA to rmtG, and npmA) and the colistin
resistancemcr-like genes (mcr-1 tomcr-5) were searched by PCR (32–35). All positive PCR amplicons were
sent for sequencing (Microsynth, Balgach, Switzerland).
Clonal relationship of the isolates was evaluated by pulsed-ﬁeld gel electrophoresis (PFGE). Total DNA
from K. pneumoniae isolates and E. coli isolates was digested using the XbaI enzyme (New England
BioLabs, Ipswich, USA). The generated fragments were separated by PFGE using a CHEF-DR III System
(Bio-Rad, Cressier, Switzerland), creating a unique PFGE proﬁle for each clonal strain. Multilocus sequence
typing (MLST) (36) was performed for one strain from each of the unique PFGE proﬁles. Sequence types
(STs) were investigated using the online databases (http://bigsdb.web.pasteur.fr/klebsiella/klebsiella.html
and https://enterobase.warwick.ac.uk/) for K. pneumoniae and E. coli isolates, respectively.
DNA of plasmids harboring the blaOXA-181, mcr-1, or rmtB genes was extracted using the Kieser
extraction method (37). Extracted plasmid DNA was then electroporated into E. coli TOP10 and selected
on LB agar plates supplemented either with temocillin (50 g/ml) for OXA-181 producers, colistin (1
g/ml) for MCR-1 producers, and amikacin (50 g/ml) plus gentamicin (50 g/ml) for RmtB producers.
Plasmid size was evaluated by agarose gel electrophoresis using E. coli NCTC50192 as a size control. It
harbors four plasmids with sizes of 154, 66, 48, and 7 kb. Plasmids were characterized by PCR-based
replicon typing (PBRT) (38). The PCR scheme was complemented with primers speciﬁc for the IncX3-type
plasmid backbones (IncX3 Fw, 5=-GAG GCT TAT CGT GAA GAC AG-3=; IncX3 Rv, 5=-GAA CGA CTT TGT CAA
ACT CC-3=) (13), as well as primers speciﬁc for IncX4 plasmids (39). The genetic environment of blaOXA-181
was investigated by PCR mapping with primers for insertion sequences ISKpn19 and IS3000, taking in
account that those mobile elements have been previously identiﬁed in the close vicinity of the blaOXA-181
gene (7, 40).
Mating-out experiments. The azide-resistant E. coli strain J53 was used as the recipient in conju-
gation assays. Donors and recipient strains were incubated separately overnight in LB broth (5 ml). After
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incubation, the donor strain and recipient were combined at a ratio of 9:1 (donor/recipient) and
centrifuged. The supernatant was removed, and the pellet was resuspended in 1 ml of LB broth, which
was plated on a 0.45-m conjugation ﬁlter on an LB agar plate. The plates were incubated for 3 h and
then plated on LB agar supplemented with sodium azide (100 g/ml) and temocillin (50 g/ml) for
blaOXA-181-positive plasmids, colistin (1 g/ml) for mcr-1-positive plasmids, and gentamicin (50 g/ml)
plus amikacin (50 g/ml) for rmtB-positive plasmids. Susceptibility testing was performed for E. coli
transconjugants for which the positivity for the respective resistance genes was checked by PCR.
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